Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology ...
-
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
-
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-endRecent Follow-on Offering and BARDA...
-
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...
-
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
-
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
-
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending dosesData support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to...
-
Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass., June 05, 2018 ...
-
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
-
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and...